What is the purpose of Epicure Epirubicin 100mg Injection?
Breast cancer patients who have had surgery to remove the tumor are given Epicure Epirubicin 100mg Injection in combination with other cancer treatments. Epirubicin belongs to a class of drugs known as antineoplastics. It inhibits the growth of cancer cells, causing them to be eliminated.
How is epirubicin administered?
Epirubicin is administered through intravenous injection (IV). The syringe needle is inserted directly into the tubing of a freely flowing IV fluid and the medicine is administered over several minutes. A vesicant is epirubicin.
What are the adverse effects of epirubicin 100mg injection?
- Side effects of Epicure Epirubicin 100mg Injection
- fast or slow heartbeats;
- easy bruising,
- unusual bleeding,
- purple or red areas under the skin;
- unusual weariness,
- or shortness of breath,
- cold hands and feet;
- or skin changes where the injection was given;
- severe vomiting; For more details Click Here.
What’s the best way to dilute Epicure Epirubicin 100mg Injection?
Epirubicin Hydrochloride for Injection 50 mg and 200 mg vials must be reconstituted with 25 mL and 100 mL of Sterile Water for Injection, USP, respectively, prior to use, resulting in a pH of 4.7 to 5.0 and a solution concentration of 2 mg/mL. Shake the bottle vigorously.
How many epirubicin cycles are there?
Epirubicin was given at a dose of 120 mg/M2 every three weeks for a total of ten cycles.
What effect does epirubicin have on the heart?
It can sometimes weaken the heart’s ability to pump blood. There is a chance that it will cause long-term heart damage in certain people. The study’s major goal was to uncover things that could assist them to figure out who is more at risk of heart damage from epirubicin.
Is epirubicin irritating to the skin?
Epirubicin should only be injected into a vein. It may, however, leak into nearby tissue, causing significant discomfort or harm.
What is the efficacy of Epicure Epirubicin 100mg Injection?
For a total of eight treatment cycles, the patients got single high doses of the medication every three weeks. The overall response rate was 79 percent, with 22 percent of respondents providing complete responses. Low blood counts were the most common side effect.